A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Zibotentan (Primary)
- Indications Kidney disorders; Renal failure; Renal impairment; Scleroderma
- Focus Biomarker; Therapeutic Use
- Acronyms ZEBRA
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2015 Accrual to date is 19% according to United Kingdom Clinical Research Network.
- 07 Aug 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network.